Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Ocugen, Inc.NASDAQ: OCGN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $590K fell 35.1% year over year, behind the -8.6% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +70.7% a year.
Context
- Depreciation & amortization amounted to 54.1% of revenue in FY2025, up 5.6 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -35.1% toward the trailing-twelve-month pace of -8.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.39M USD
- Year-over-year change
- +21.4%
- 4-year CAGR
- +79.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.39M | +21.4% |
| FY2024 | 2024-12-31 | 1.97M | +179.5% |
| FY2023 | 2023-12-31 | 704K | +46.7% |
| FY2022 | 2022-12-31 | 480K | +109.6% |
| FY2021 | 2021-12-31 | 229K | — |
Depreciation & Amortization vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 depreciation & amortization of $2.47M is the 3rd highest of the 10 companies compared; the peer median is $1.12M.
- Its year-over-year change of -8.6% is the 5th highest of 10, against a peer median of -11.7%.
- Depreciation & amortization amounts to 55.3% of revenue for OCGN, versus a peer median of 4.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.18M | +0.0% | -1.1% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.65M | -20.7% | +140.9% | 35.9% |
| LTM Mar 2026 | $2.47M | -8.6% | +70.7% | 55.3% | |
| LTM Mar 2026 | $1.38M | -6.3% | -16.8% | — | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Mar 2026 | $1.12M | -32.0% | -8.2% | — | |
| LTM Mar 2026 | $914K | -11.7% | +0.4% | 9.2% | |
| LTM Mar 2026 | $723K | +20.9% | -1.3% | 4.9% | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
| Peer median (excluding OCGN) | $1.12M | -11.7% | -1.3% | 4.9% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.49M | 6.04M | 4.06M | 4.41M |
| Cost of Revenue | 0 | 0 | 704K | 1.97M | 2.39M |
| Gross Profit | 0 | 2.49M | 5.33M | 2.09M | 2.02M |
| Gross Margin | — | 100.0% | 88.3% | 51.5% | 45.9% |
| Research & Development | 35.11M | 56.16M | 39.57M | 32.13M | 39.75M |
| Selling, General & Admin | 22.92M | 35.4M | 31.99M | 26.69M | 27.58M |
| Operating Expenses | 58.03M | 91.56M | 70.86M | 56.84M | 64.94M |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| EBITDA | (58.11M) | (86.32M) | (62.37M) | (52.09M) | (60.27M) |
| EBITDA Margin | — | -3469.6% | -1033.4% | -1284.5% | -1365.7% |
| Operating Income | (58.03M) | (89.07M) | (65.53M) | (54.76M) | (62.92M) |
| Operating Margin | — | -3580.0% | -1085.7% | -1350.4% | -1425.7% |
| Interest Income | 0 | 1.4M | 2.5M | 1.3M | 922K |
| Interest Expense | 79K | 0 | 0 | 0 | 5.19M |
| Other Income / Expenses | (389K) | 2.27M | 2.45M | 703K | (4.93M) |
| Income Before Tax | (58.42M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Pre-Tax Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| Income Tax Expense | (52K) | 0 | 0 | 0 | 0 |
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Net Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| EPS (Basic) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| EPS (Diluted) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| Weighted Avg Shares | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
| Weighted Avg Shares (Diluted) | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.